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Summary A novel peritoneal carrier solution, Icodextrin 20 (7.5%), has allowed exploration of prolonged,
intraperitoneal (i.p.) infusion of the cytotoxic drug 5-fluorouracil (5-FU). A phase I and pharmacokinetic study
was performed to determine the toxicities and maximum tolerated dose of prolonged and continuous
intraperitoneal 5-FU in patients with peritoneal carcinomatosis. Seventeen patients were entered into this
study. Each patient had a Tenckhoff catheter placed into the peritoneal cavity under general anaesthetic. After
initial flushing and gradual increase in exchange volumes with Icodextrin 20, 5-FU was administered daily from
Monday to Friday, 50% as a bolus in the exchange bag and 50% in an elastomeric infusor device delivering
continuous 5-FU to the peritoneal cavity at 2 ml h-'. Treatment was continued for 12 weeks or until
intolerable toxicity developed. Abdominal pain and infective peritonitis proved to be the main dose-limiting
toxicities. Initial problems with infective peritonitis were overcome by redesign of the delivery system, and it
proved possible to deliver 300 mg m 2 5-FU daily (5 days per week) for 12 weeks. Pharmacokinetic studies
showed i.p. steady-state 5-FU concentrations (mean 47 500 ng ml-') that were > 1000-fold higher than
systemic venous levels (mean 30 ng ml-').
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There has been an extraordinary increase in the use of 5-FU-
based adjuvant chemotherapy for colorectal cancer patients,
although there is continuing debate about the size of the
survival benefit conferred (Gray et al., 1991). Common sites
of relapse following apparently curative resection of color-
ectal primary cancers include the site of anastomosis, the
peritoneal cavity and the liver. Seventy-four per cent of
patients who relapse have either loco-regional recurrence or
peritoneal seedlings, or both. More than 10% of all cases
recur solely in the liver (Cunliffe and Sugarbaker, 1989).
There have been sporadic attempts to develop adjuvant
regional chemotherapy for colorectal cancer with intermittent
cytotoxic drug delivery to the peritoneal cavity, based on the
premise that anti-cancer drugs have steep dose - response
curves. Previous pharmacokinetic studies following intraper-
itoneal (i.p.) administration of 5-FU (12-36 h) have shown
that it is possible to generate very high i.p. 5-FU
concentrations and that 70% of the drug is cleared by the
portal circulation to the liver (Speyer et al., 1981).
Additionally, as 5-FU is a soluble compound of relatively
small molecular weight, it diffuses more rapidly and
homogeneously into tumour nodules, unlike cisplatin which
tends to localise to the external cell layer. This implies that it
will have a better 'tumour penetration' profile than many
other cytotoxic agents that have been administered i.p. (Kerr
and Los, 1993). Intraperitoneal therapy would seem to meet
ideal criteria for delivery of the cytotoxic drug to sites of
likely disease recurrence.
5-FU is a cycle-specific antineoplastic agent, and recent
trials imply that prolonged intravenous infusion (12 weeks) is
clinically superior to intermittent bolus administration
(Lokich et al., 1989). However, the nature of conventional
peritoneal dialysate solutions militates against prolonged i.p.
exposure unless multiple dialysate exchanges are undertaken,
with a consequently increased likelihood of infective
peritonitis. The invention of a novel polymeric carrier
solution, Icodextrin (7.5%) (ML Laboratories), with a
potential i.p. dwell time of 24 h (McArdle et al., 1994) led
us to undertake a phase I, toxicology and pharmacokinetic
study of prolonged i.p. infusional 5-FU in patients with
intraperitoneal carcinomatosis from ovarian or gastrointest-
inal malignancies refractory to conventional therapy or for
whom no standard treatment existed.
Methods
Patient selection
Seventeen patients with peritoneal carcinomatosis gave
informed consent for insertion of a Tenckhoff peritoneal
dialysis catheter (Baxter Healthcare) under general anaes-
thetic, through a mini-laparotomy incision, with perioperative
antibiotic cover comprising cefuroxime 1.5 g i.v., metronida-
zole 500 mg i.v. and cefuroxime 750 mg i.p. On return from
theatre, after initial flushing, 300 ml of Icodextrin 20 (7.5%)
was administered using a specially designed twin-bag system
(Baxter Healthcare) (Figure 1). Specialist nurses performed
daily exchanges for the next week, gradually increasing the
volume instilled to an average of 900 ml (range 600-
1750 ml) depending on the size of the patient. All patients
were taught an aseptic technique for performing their own
exchange at home. Homogeneous distribution of fluid
throughout the peritoneal cavity was confirmed by ultra-
sound and, in one patient by PET scanning (in collaboration
with Dr P Price, the Cyclotron Unit, Hammersmith Hospital,
London, UK), following i.p. administration of 5-'8FU
revealed that the drug was distributed as widely as the
dialysate.
Patients' characteristics are summarised in Table I.
Chemotherapy regime
Chemotherapy commenced 10 days after insertion of the
catheter, initially at a 5-FU dose of 200 mg m-2 per day (five
patients) and then 300 mg m-2 per day (seven patients). The
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Figure 1 Intraperitoneal drug delivery system. The system
contains an intraperitoneal implantable Tenckhoff catheter (A)
connected to the integrated twin-bag disconnected system (C) via
a CAPD extension line (B). A drainage container (Cl) and a 2-1
carrier solution container (C2) constitute the integrated twin-bag
system. An elastomeric infusion device (Infusor) (D) permits
continuous infusion of 5-FU over 24h.
Table I Patient characteristics
No. ofpatients
Sex
Male
Female
Age
Range
Median
Prior treatment
None
Surgery only
Chemotherapy only
Surgery +chemotherapy
Tumour type
Colorectal
Ovarian
Gastric
7
10
21-75
55
10
5
10
4
3
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48 ml) for 24 h using an elastomeric infusion device
(Singleday infusor, Baxter Healthcare) (Figure 1). Che-
motherapy was given daily from Monday to Friday. At
weekends, an exchange of Icodextrin alone was carried out.
Patients were taught by specialist intraperitoneal che-
motherapy (IPC) nurses to administer their own chemother-
apy at home and attended weekly for physical examination,
estimation of serum biochemistry and haematology, and
supply of the following week's chemotherapy for home
exchanges. Fluid balance was assessed by measuring the
volume of dialysate effluent after the 24 h i.p. dwell.
Treatment was continued for 12 weeks or until development
of intolerable toxicity.
Pharmacokinetic studies
Pharmacokinetic studies were performed in six patients
during the first week of chemotherapy, when multiple
samples were withdrawn simultaneously from the i.p.
catheter and an indwelling intravenous catheter at the
following intervals, timed from the start of the dialysate
exchange: 0, 2, 4, 6, 12 and 24 h. The samples were held on
ice, centrifuged and the supernatant stored at -20°C until
analysed by a sensitive and specific GC-MS assay in our
laboratory (Bates et al., 1991).
Results
Toxicity profile
The toxicity profile is summarised in Table II. The most
consistent problem that interrupted therapy was infective
peritonitis (one episode every 12 catheter-weeks). Aspergillus
and Pseudomonas were isolated from two cases and the
diagnosis of infective peritonitis was supported in two other
patients with the diagnostic triad of severe abdominal pain,
elevated peritoneal white cell count (>200 x 1091-') and
cloudy peritoneal effluent. Potential causes of the high
peritonitis rates included a delivery system that afforded
inadequate microbiological protection, a steep learning curve
on behalf of patients and impairment of the serosal barrier
to infection (we documented relative i.p. hypocomplement-
aemia in our patients: C3, 0.11 g 1-; C4 0.02 g I-'; normal
ranges: C3 0.75 1.75 g 1-'; C4, 0.14-0.54 g 11). No signifi-
cant 5-FU-related systemic toxicity was seen at 200 mg m-2
per day, therefore the dose was escalated to 300 mg m-2 per
day. After treating 14 patients, we redesigned the dialysis
delivery set, dispensing with the T-set and using one
connection point only, protected with a Povidone/iodine
shield. Since this change, there have been no further episodes
of peritonitis (26 catheter-weeks). Although there were no
further episodes of infective peritonitis, it was noted that
patients treated for more than 6 weeks at 300 mg m-2
suffered significant abdominal pain (WHO grades 2 and 3)
and tenderness without elevated peritoneal white cell counts,
which was consistent with moderate chemical peritonitis.
This was reduced somewhat by oral analgesics, but it was
not considered likely that the dose of 5-FU could be
Table II Toxicity in 5-FU-treated patients
Total
Dose Number number
level of of WHO toxicity codes
(mf patients catheter Abdominal pain Infective peritonitis Lethargy Anorexia Constipation Nausea and vomiting
m ) entered weeks 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4
200 5 31 1(4) 2(7) 2(2) 1(1) 1(1)
300 7 75 2(6) 2(4) 2(3)a 1(1) 1(1) 1(2) 4(12) 2(2)
Reported as worst related toxicity per patient at each dose level -the number ofpatient-weeks experienced is shown in brackets. Five patients
with catheter in situ did notcommence chemotherapy because ofcatheter-related problems. Diarrhoea (grade 2) was seen in onepatienttreatedwith
200 mgm-2 5-FU. Ifthere was no toxicity (WHO grade 0), this is not recorded in the table. aNo organism was grown from the peritoneal fluid of
these patients.Intraperitoneal chemotherapy
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escalated further without a reduction in the duration of
therapy.
Duration of treatment
Five patients failed to reach the chemotherapy stage-two
patients had inadequate distribution of intraperitoneal
fluid, one patient had an exit site infection, one patient
died post-operatively as a result of a pulmonary embolism
and one patient had a bowel obstruction. Twelve patients
had chemotherapy, five at 200 mg m-2 and seven at
300 mg m-2. Individual treatment duration of the 12
patients who received chemotherapy is shown in Table
III.
Pharmacokinetic studies
Pharmacokinetic studies revealed that it was possible to
generate average i.p. 5-FU concentrations of 30 000 ng ml-'
(range 23 000-35 000 ng ml-) and corresponding systemic
venous levels of 6 ng ml-' (range 1.9-13.7 ng ml-') for a
dose of 200 mg m-2, and mean i.p. 5FU concentrations of
47 500 ng ml-' (range 29 000-72 000 ng ml-') and asso-
ciated mean venous levels of 30 ng ml-' (range 11 -
55 ng ml-') for a dose of 300 mg m-2 (Figure 2).
The regional advantage accrued from i.p. infusional 5-FU
is expressed as a ratio of i.p./plasma concentrations (mean
6500, range 536-16724) (Table IV). It was not possible to
determine a terminal half-life for 5-FU as plasma concentra-
tions were relatively close to the limit of detection and the
brief terminal half-life of the drug. There was no clear
Table III Treatment outcome
Number ofpatients
discontinued treatment-
primary disease
gastric
ovarian
colorectal
colorectal
ovarian
ovarian
colorectal
gastric
colorectal
colorectal
colorectal
colorectal
Reason off-study
Disease progression
Catheter blockage
Absorbing fluid
Increasingly poor
distribution
Peritonitis
Disease progression
Disease progression
Peritonitis
Peritonitis
Weight loss
Weight loss
Completed study
evidence of circadian variation in plasma 5-FU concentra-
tions; however, this could relate to the number of samples
taken.
Follow-up
Of those 12 patients who received treatment, eight have died
(median 10 weeks after end of treatment). Four patients
completed more than 8 weeks of treatment, one patient
completing 12 weeks. As shown, disease progression and
peritonitis were the main reasons for patients being taken off-
study early. Of the four patients who had over 8 weeks of
treatment, three are alive and well 10-20 months after
treatment completion. One such patient had multiple
peritoneal metastases at time of insertion of the i.p. catheter.
Discussion
It would appear that prolonged intraperitoneal infusion of 5-
FU, 300 mg mr2 per day, is tolerable and generates the sort
of pharmacokinetic profile that will take full advantage of the
steep dose-response curve for 5-FU, namely very high
concentrations within the peritoneal cavity covering perito-
neal dissemination of disease and local recurrence; approxi-
mately 70% clearance via the portal venous circulation
(Speyer et al., 1981), dealing with micrometastases to the
liver, with the remainder of the drug being cleared through
retroperitoneal lymphatics; and mean plasma levels of 5-FU
similar to those described for venous infusions of 5-FU
(Harris et al., 1990), providing cover for extrahepatic
micrometastases.
Previous, small, randomised studies of adjuvant i.p. 5-FU
in colorectal cancer have used intermittent high-dose regi-
mens (dose intensity = 2.3 g m-2 per week) that do not
make best use of the cell cycle-specific cytotoxic properties of
5-FU (Cunliffe and Sugarbaker, 1989). There is clinical
evidence suggesting that prolonged intravenous infusion of 5-
FU results in superior response rates in advanced colorectal
cancer, compared with intermittent bolus therapy, lending
clinical weight to the pharmacological rationale for contin-
uous exposure to 5-FU (Lokich et al., 1989).
One other pharmacological benefit that 5-FU enjoys
relative to many other antineoplastic drugs that have been
administered via the peritoneal route is its capacity to diffuse
relatively homogeneously through tumour tissue (Erlanson et
al., 1992). It has been shown that other cytotoxic drugs, such
as doxorubicin (Kerr and Kaye, 1987), vinblastine (Neder-
man et al., 1981) and methotrexate (West et al., 1980), are
quite limited in their capacity to diffuse down a concentration
gradient into multicellular tumour spheroids in vitro or
peritoneal tumour nodules in vivo. This has been considered
to be one of the dominant reasons limiting the clinical
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Figure 2 5-FU levels in peritoneum and plasma.
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Table IV Pharmacokinetic results
Peritoneal Plasma Regional advantage
Patient Total i.p. 5-FU dose AUC Mean conc. AUC Mean conc. Peritoneal/Plasma ratio
ID delivered (mg) (mgl' h) (mgrF') (mglt h) (mgl ) AUC Mean conc.
200mgm 2 dose
1 304 1010 30.5 0.379 0.0137 2665 2223
2 416 765 23.1 0.129 0.0019 5933 12 168
3 300 976 35.1 0.145 0.0021 6730 16724
300mgm 2 dose
4 600 - 29.2 - 0.055 - 536
5 534 2003 72.1 0.58 0.022 3453 3 277
6 496 969 41.2 0.379 0.011 2557 3 746
AUC, area under the concentration- time curve. conc., concentration.
development of i.p. chemotherapy, and lack of tumour
penetration could contribute significantly to relative drug
resistance (Kerr and Los, 1993).
In the same way that prolonged i.v. infusions of 5-FU did
not become widely established until technical innovation
resulted in increased pump reliability, i.p. chemotherapy has
suffered from a lack of research into improved drug delivery
systems. During this study, the chemotherapy-giving set was
successfully redesigned to reduce the possibility of bacterial
contamination and hence peritonitis. The peritoneal dialysate
Icodextrin 7.5% is a macromolecular starch-based polymer
similar in structural to glycogen, i.e. non-toxic and broken
down in the body by natural carbohydrases. It was developed
to increase the peritoneal dwell time of the dialysis fluid,
improve control of toxicity and fluid balance and perhaps
reduce the possibility of the peritoneal diabetes characteristic
of prolonged continuous peritoneal dialysis with conventional
low molecular weight dialysates for use in patients with renal
failure. The physicochemical properties of Icodextrin greatly
simplify drug delivery and make i.p. therapy potentially much
more widely applicable.
There is a renewal of interest in i.p. chemotherapy as a
result of the recent publication of the positive results of the
randomised SWOG/GOG/ECOG study, favouring i.p. over
i.v. chemotherapy (Alberts et al., 1995). It was demonstrated
that a subgroup of ovarian cancer patients with small volume
disease (stage III) showed increased survival by a median of
10 months after i.p. cisplatin compared with i.v. cisplatin
(with all patients receiving i.v. cyclophosphamide). Further-
more, a number of experimental and clinical studies have
indicated that i.p. therapy in patients with large bulky disease
will not improve i.v. treatment in spite of the fact that
virtually all agents demonstrated a pharmacological advan-
tage when administered to the peritoneal cavity. The reason
for this is that cytostatic drugs penetrate poorly into
tumours, resulting in higher drug levels only in the outer
cell layers of peritoneal tumours. Consequently, a few cell
layers with high drug concentrations will not eradicate large
tumour masses. Therefore, patients most likely to benefit
from the i.p. therapy are those with a small tumour volume
at the start of treatment. In addition, the better the
'penetration pattern' or diffusibility of the cytotoxic agent,
the greater the likelihood of benefits. Icodextrin provides a
greater variety of i.p. drug administration schedules,
particularly for cycle-specific drugs, therefore we plan to
draw these different strands together and conduct a pilot
study using the schedule described in this report for i.p.
chemotherapy in an adjuvant setting, following resection of
primary bowel cancer.
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